Novel FTY720-based compounds stimulate neurotrophin expression and phosphatase activity in dopaminergic cells

ACS Medicinal Chemistry Letters

Volumn 5, Issue 7, 2014, Pages 782-786

  Vargas Medrano, Javier ^a   Krishnamachari, Sesha ^a   Villanueva, Ernesto ^a   Godfrey, Wesley H ^a   Lou, Haiyan ^b   Chinnasamy, Ramesh ^c   Arterburn, Jeffrey B ^c   Perez, Ruth G ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NEW MEXICO STATE UNIVERSITY   (United States)

Author keywords

BDNF; ceramides; Parkinsons; PP2A; synucleinopathy; triphenylphosphonium; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CERAMIDE; FINGOLIMOD; NEUROPROTECTIVE AGENT; NEUROTROPHIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG POTENCY; ENZYME ACTIVITY; MITOCHONDRION; MOUSE; NEUROPROTECTION; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84904340296     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500128g     Document Type: Article

References (32)

1. Dobrowsky, R. T.; Kamibayashi, C.; Mumby, M. C.; Hannun, Y. A. Ceramide activates heterotrimeric protein phosphatase 2A J. Biol. Chem. 1993, 268 (21) 15523-30
2. Mumby, M. C.; Walter, G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth Physiol. Rev. 1993, 73 (4) 673-99
3. Gotz, J.; Schild, A. Transgenic and knockout models of PP2A Methods Enzymol. 2003, 366, 390-403
4. Dagda, R. K.; Zaucha, J. A.; Wadzinski, B. E.; Strack, S. A developmentally regulated, neuron-specific splice variant of the variable subunit Bbeta targets protein phosphatase 2A to mitochondria and modulates apoptosis J. Biol. Chem. 2003, 278 (27) 24976-85
5. Peng, X.; Tehranian, R.; Dietrich, P.; Stefanis, L.; Perez, R. G. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells J. Cell Sci. 2005, 118 (Pt 15) 3523-30
6. Lou, H.; Montoya, S. E.; Alerte, T. N.; Wang, J.; Wu, J.; Peng, X.; Hong, C. S.; Friedrich, E. E.; Mader, S. A.; Pedersen, C. J.; Marcus, B. S.; McCormack, A. L.; Di Monte, D. A.; Daubner, S. C.; Perez, R. G. Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo J. Biol. Chem. 2010, 285 (23) 17648-61
7. Perez, R. G.; Waymire, J. C.; Lin, E.; Liu, J. J.; Guo, F.; Zigmond, M. J. A role for alpha-synuclein in the regulation of dopamine biosynthesis J. Neurosci. 2002, 22 (8) 3090-9
8. Goedert, M.; Spillantini, M. G.; Del Tredici, K.; Braak, H. 100 years of Lewy pathology Nat. Rev. Neurol. 2013, 9 (1) 13-24
9. Wu, J.; Lou, H.; Alerte, T. N.; Stachowski, E. K.; Chen, J.; Singleton, A. B.; Hamilton, R. L.; Perez, R. G. Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo Neuroscience 2012, 207, 288-97
10. Gong, C. X.; Singh, T. J.; Grundke-Iqbal, I.; Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain J. Neurochem. 1993, 61 (3) 921-7
11. Parihar, M. S.; Parihar, A.; Fujita, M.; Hashimoto, M.; Ghafourifar, P. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells Int. J. Biochem. Cell Biol. 2009, 41 (10) 2015-24
12. Farrell, K. F.; Krishnamachari, S.; Villanueva, E.; Lou, H.; Alerte, T. N. M.; Peet, E.; Drolet, R. E.; Perez, R. G. Non-motor parkinsonian pathology in aging A53T α-Synuclein mice is associated with progressive synucleinopathy and altered enzymatic function J. Neurochem. 2014, 128 (4) 536-546
13. Lee, K. W.; Chen, W.; Junn, E.; Im, J. Y.; Grosso, H.; Sonsalla, P. K.; Feng, X.; Ray, N.; Fernandez, J. R.; Chao, Y.; Masliah, E.; Voronkov, M.; Braithwaite, S. P.; Stock, J. B.; Mouradian, M. M. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model J. Neurosci. 2011, 31 (19) 6963-71
14. Oaks, J. J.; Santhanam, R.; Walker, C. J.; Roof, S.; Harb, J. G.; Ferenchak, G.; Eisfeld, A. K.; Van Brocklyn, J. R.; Briesewitz, R.; Saddoughi, S. A.; Nagata, K.; Bittman, R.; Caligiuri, M. A.; Abdel-Wahab, O.; Levine, R.; Arlinghaus, R. B.; Quintas-Cardama, A.; Goldman, J. M.; Apperley, J.; Reid, A.; Milojkovic, D.; Ziolo, M. T.; Marcucci, G.; Ogretmen, B.; Neviani, P.; Perrotti, D. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies Blood 2013, 122, 1923-34
15. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat. Rev. Drug Discovery 2010, 9 (11) 883-97
16. Oderda, G.; Archer, M. Fingolimod (Gilenya®) Drug Review. University of Utah College of Pharmacy: Final Report, 2013.
17. Di Pardo, A.; Amico, E.; Favellato, M.; Castrataro, R.; Fucile, S.; Squitieri, F.; Maglione, V. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease Hum. Mol. Genet. 2014, 23 (9) 2251-65
18. Van Brocklyn, J. R.; Williams, J. B. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. 2012, 163 (1) 26-36
19. Sim-Selley, L. J.; Goforth, P. B.; Mba, M. U.; Macdonald, T. L.; Lynch, K. R.; Milstien, S.; Spiegel, S.; Satin, L. S.; Welch, S. P.; Selley, D. E. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS J. Neurochem. 2009, 110 (4) 1191-202
20. Wei, Y.; Yemisci, M.; Kim, H. H.; Yung, L. M.; Shin, H. K.; Hwang, S. K.; Guo, S.; Qin, T.; Alsharif, N.; Brinkmann, V.; Liao, J. K.; Lo, E. H.; Waeber, C. Fingolimod provides long-term protection in rodent models of cerebral ischemia Ann. Neurol. 2011, 69 (1) 119-29
21. Gao, F.; Liu, Y.; Li, X.; Wang, Y.; Wei, D.; Jiang, W. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model Pharmacol., Biochem. Behav. 2012, 103 (2) 187-96
22. Deogracias, R.; Yazdani, M.; Dekkers, M. P.; Guy, J.; Ionescu, M. C.; Vogt, K. E.; Barde, Y. A. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (35) 14230-5
23. Porras, J. L.; Perez, R. G. Potential Contribution of Alpha-Synuclein Dysregulation to Parkinsons Disease Pathology. In Alpha-Synuclein; Kanowitz, M. P. a. H. C., Ed.; NOVA Science Publishers: New York, 2014.
24. Mencarelli, C.; Martinez-Martinez, P. Ceramide function in the brain: when a slight tilt is enough Cell. Mol. Life Sci. 2013, 70 (2) 181-203
25. Chalfant, C. E.; Kishikawa, K.; Mumby, M. C.; Kamibayashi, C.; Bielawska, A.; Hannun, Y. A. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid J. Biol. Chem. 1999, 274 (29) 20313-7
26. Toman, R. E.; Movsesyan, V.; Murthy, S. K.; Milstien, S.; Spiegel, S.; Faden, A. I. Ceramide-induced cell death in primary neuronal cultures: upregulation of ceramide levels during neuronal apoptosis J. Neurosci. Res. 2002, 68 (3) 323-30
27. Miron, V. E.; Schubart, A.; Antel, J. P. Central nervous system-directed effects of FTY720 (fingolimod) J. Neurol. Sci. 2008, 274 (1-2) 13-7
28. Perrotti, D.; Neviani, P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias Cancer Metastasis Rev. 2008, 27 (2) 159-68
29. Exner, N.; Lutz, A. K.; Haass, C.; Winklhofer, K. F. Mitochondrial dysfunction in Parkinsons disease: molecular mechanisms and pathophysiological consequences EMBO J. 2012, 31 (14) 3038-62
30. Reily, C.; Mitchell, T.; Chacko, B. K.; Benavides, G.; Murphy, M. P.; Darley-Usmar, V. Mitochondrially targeted compounds and their impact on cellular bioenergetics Redox Biol. 2013, 1 (1) 86-93
31. Martinez, T. N.; Chen, X.; Bandyopadhyay, S.; Merrill, A. H.; Tansey, M. G. Ceramide sphingolipid signaling mediates tumor necrosis factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons Mol. Neurodegener. 2012, 7, 45
32. Ugarte, S. D.; Lin, E.; Klann, E.; Zigmond, M. J.; Perez, R. G. Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: Modulation by inhibitors of PI3 kinase and MEK J. Neurosci. Res. 2003, 73 (1) 105-112